# CURB: SBRT for oligoprogressive breast or non-small-cell lung cancer

Source: https://onco.cc/trials/curb-oligoprogression/  
OnCo record `curb-oligoprogression` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CURB tested added SBRT for limited progression during systemic treatment. Its lung and breast subgroup findings should not be combined into one rule for every metastatic cancer.

## Summary

The randomised phase 2 report compared standard care with or without SBRT in 106 participants, including 59 with NSCLC and 47 with breast cancer. Progression-free survival began at randomisation. The overall comparison favoured added SBRT; the prespecified lung subgroup showed a benefit and the breast estimate was imprecise and nonsignificant.

The captured registry lists active, not recruiting status and estimated 2027 completion. That administrative status is distinct from the published 2024 analysis or current availability at a site. It does not make the report a study in every oligoresidual or first-line limited-metastatic setting.

## Fields

- Kind: Trial
- Status: mixed
- Last checked: 2026-11-09
- Also known as: CURB oligoprogression trial; PROMISE-004
- Tags: education-audit; local-treatment
- Registry id: NCT03808662
- Phase: 2
- Setting: Metastatic breast cancer or NSCLC after at least first-line systemic treatment, with no more than five progressing lesions: SBRT plus standard care versus standard care
- Sponsor: Memorial Sloan Kettering Cancer Center
- Enrolled: 106
- Result: Overall progression-free survival hazard ratio 0.53; breast subgroup 0.78 with 95 percent confidence interval 0.43 to 1.43. The latter does not establish exactly zero effect.
- Outcomes: Progression-free survival from randomisation, overall 2024 report: SBRT plus standard care 7.2 months vs Standard care 3.2 months, HR 0.53; Progression-free survival, prespecified NSCLC subgroup: SBRT plus standard care 10 months vs Standard care 2.2 months, HR 0.41; Progression-free survival, prespecified breast subgroup: SBRT plus standard care 4.4 months vs Standard care 4.2 months, HR 0.78

## Sources

- ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03808662
- Original randomised report: https://pubmed.ncbi.nlm.nih.gov/38104577/

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- key papers: [CURB: adding SBRT for oligoprogressive breast or non-small-cell lung cancer](https://onco.cc/key-papers/paper-curb-oligoprogression-lancet-2024/)
- people: [Charles M. Rudin](https://onco.cc/people/charles-rudin/), [Mark E. Robson](https://onco.cc/people/mark-robson/), [Michael F. Berger](https://onco.cc/people/michael-berger/), [Shanu Modi](https://onco.cc/people/shanu-modi/)

---
JSON: https://onco.cc/api/v1/entities/curb-oligoprogression.json